[Becky]

Abraxane and Avastin - this was a non randomized trial and the nice thing is that patients enrolled could be on their 2nd, 3rd or even 4th line of therapy for metastatic disease. The women randomized to Abraxane with Avastin did 50% better than Abraxane alone. This proves to oncologists that Avastin can work even in heavily pretreated metastatic women and 50% more time to progression got a huge clap.

17AAG trial for Her2+ metastatic disease.

17AAG is a targeted therapy for metastatic Her2+ bc. 17AAG is a heat shock protein 90 inhibitor. It inhibits Her2 to be able to unfold and go through the chemical reactions it needs to in order to be active (basically shutting down Her2 activity). This molecule, tested in only a few women who were Herceptin resistant, had great activity and is a promising new molecule that works in a different way, in a different pathway, that either Herceptin or Tykerb (thus - more combinations of Targeted therapies that could have syngergies with each other)

Tykerb and Taxol in IBC HER2+ metastatic disease

This trial showed that 80% of women had some response (complete, partial or stable) which is astounding in this aggressive form of Her2.